Fig. 3From: Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?Overall survival and progression-free survival curves according to p53 antibody status for the KRAS wild-type population (n = 44)Back to article page